Read before the Section for Clinical Medicine, Pathology, and Hygiene of the Suffolk District Medical Society, June 9, 1885.
- Taldefgrobep alfa, a myostatin-targeting biologic investigational agent, in Phase 3 development to increase muscle mass for Spinal Muscular Atrophy patients now granted Fast Track in addition to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results